ACADIA Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard
San Diego,
CA 92121
United States - Map
Phone: 858-558-2871
Fax: 858-558-2872
Web Site: http://www.acadia-pharm.com
| ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It focuses on developing a portfolio of its four advanced product candidates, including Pimavanserin, which is in phase III development for Parkinsons disease psychosis; and a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, each in collaboration with Allergan, Inc., as well as ACP-106 in IND-track development for neuropsychiatry and sleep indications. Pimavanserin is also in a phase II trial as a co-therapy in schizophrenia and in a proof-of-concept clinical study for sleep maintenance insomnia. ACADIA Pharmaceuticals development pipeline also consists of ACP-105 for endocrine indications in IND-track development stage; Serotonin program for neuropsychiatry and sleep indications in preclinical stage; pro-cognitive antipsychotic (PCAP) program for schizophrenia in preclinical stage; Muscarinic program for neuropsychiatry and other indications; and two series of compounds for Parkinsons disease. It has a collaboration agreement with Biovail Laboratories International SRL to co-develop and commercialize pimavanserin in the United States and Canada. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Uli Hacksell Ph.D., 60
Chief Exec. Officer |
$
463.00K |
$
13.00K | Mr. Thomas H. Aasen CPA, 49
Chief Financial Officer, Principal Accounting Officer, VP, Sec. and Treasurer |
$
302.00K |
$
125.00K | Dr. Roger G. Mills M.D., 52
Exec. VP of Devel. |
$
361.00K |
$
0 | Ms. Lisa Barthelemy ,
Director of Investor Relations |
N/A
| N/A | Dr. Daniel P. Van Kammen M.D., Ph.D.,
VP of Clinical Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.43% Nasdaq 
Profile
